Quest Diagnostics Completes Acquisition of Select PathAI Diagnostics' Lab Assets from PathAI, Accelerating Adoption of AI and Digital Pathology to Speed Cancer DiagnosisPRNewsWire • 06/11/24
Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health ForumPRNewsWire • 05/31/24
Why Is Quest Diagnostics (DGX) Up 3.1% Since Last Earnings Report?Zacks Investment Research • 05/23/24
Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of DirectorsPRNewsWire • 05/16/24
Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug TestsPRNewsWire • 05/15/24
Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads ConferencePRNewsWire • 05/07/24
Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital OfficerPRNewsWire • 05/06/24
Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAIPRNewsWire • 05/01/24
FDA brings lab tests under federal oversight in bid to improve accuracy and safetyMarket Watch • 04/29/24
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024PRNewsWire • 04/23/24
Unlocking Q1 Potential of Quest Diagnostics (DGX): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 04/22/24
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's DiseasePRNewsWire • 04/22/24
Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to DeclineZacks Investment Research • 04/16/24
Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental DelayPRNewsWire • 04/02/24